The study of rare cancers has undergone a paradigm shift, transitioning from a singular disease entity approach to a more nuanced understanding of biomarker-defined subtypes.
Amy O’Sullivan, PhD
Advertisement
Articles by Amy O’Sullivan, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Talazoparib/Enzalutamide in HRR-Mutated Prostate Cancer
2
ADCs Shine, Mixed Bag for Immunotherapy at ESMO 2026 Presidential Symposium III
3
ESMO 2026: Survival Gains and New Treatment Strategies in GI Cancers
4
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
5